E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Pregnant women with Gestational Diabetes Mellitus (GDM) |
Diabète gestationnel |
|
E.1.1.1 | Medical condition in easily understood language |
Pregnant women with Gestational diabetes mellitus (GDM) |
Diabète Gestationnel chez la femme enceinte |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Nutritional and Metabolic Diseases [C18] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 19.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10018209 |
E.1.2 | Term | Gestational diabetes |
E.1.2 | System Organ Class | 10036585 - Pregnancy, puerperium and perinatal conditions |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To test whether oral acarbose is non-inferior to subcutaneous prandial insulin for the occurrence of perinatal complications in the management of pregnant women developing GDM and requiring treatment other than diet to control post-prandial glucose values. |
Tester si le traitement par acarbose orale n'est pas inférieur au traitement par insuline prandiale sous-cutanée dans la survenue de complications périnatales chez les femmes enceintes qui développent une diabète gestationnel et nécessitent un traitement autre que le régime alimentaire pour contrôler leur glycémie post-prandiale. |
|
E.2.2 | Secondary objectives of the trial |
A. To compare the two treatment strategies on maternal glycaemic control
B. To compare the acarbose arm and the prandial insulin arm on maternal and neonatal complications
C. To test the acceptance/satisfaction of the two strategies
D. To compare the acarbose and insulin on side effects
E. To evaluate maternal and offspring short term follow-up (3 months after delivery)
F. Conservation of serum and cord fluid at the time of delivery |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
- Age > ou = 18 years
- Singleton pregnancy
- GDM diagnosed during pregnancy according to IADPSG criteria, i. e.
o fasting plasma glucose between 92 mg/dL (5.1 mmol/L) and 125 mg/dL (6.9 mmol/L)
o and/or 1-hour plasma glucose value after 75 g oral glucose tolerance test (OGTT)
o > ou = 180 mg/dL (10.0 mmol/L)
o and/or 2-hour plasma glucose value between 153 mg/dL (8.5 mmol/L) and 199 mg/dL ((11.0 mmol/L)
- Self-monitoring of blood glucose
- After at least 7 days of dietary and lifestyle measures, unreached post-prandial glucose control (at least two capillary 2-hour post-prandial glucose values >1.20 g/l ((6.6 mmol/L))
- 12 to 34 weeks of gestation at the time of randomization
- Signed informed consent |
|
E.4 | Principal exclusion criteria |
- Prandial insulin use before randomization during this pregnancy
- Use of other oral hypoglycemic agents during this pregnancy
- Multiple pregnancy
- Known hepatic insufficiency (bilirubin > 50 µmol/L and/or TP<50%)
- Long time corticosteroids treatment
- Pre-existing diabetes in pregnancy
- Overt diabetes diagnosed during pregnancy:
o fasting plasma glucose > ou = 126 mg/dL (7 mmol/l)
o and/or 2-hour post OGTT plasma glucose value ? 200 mg/dL (11.1 mmol/L)
- Lack of Social Insurance
- Insufficient understanding
- Participant in another investigational drug study at inclusion visit
- Contraindications of acarbose:
o documented hypersensitivity to acarbose
o diabetic ketoacidosis
o cirrhosis
o inflammatory bowel disease
o colonic ulceration, partial intestinal obstruction or predisposed to intestinal obstruction
o known marked absorptive impairment
o known renal impairment (creatinine clearance < 25 ml/min)
-fetal malformation diagnosed by previous fetal ultrasound |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Composite endpoint: birth weight ≥ 90th percentile for gestational age (large for gestational age: LGA) and/or neonatal hypoglycemia and/or shoulder dystocia and/or birth injury |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
A. Capillary glucose levels / Need for prandial insulin in the acarbose arm / Need for basal insulin
B. Birth weight ≥ 4000g / Birth weight ≥ 4500g / Preeclampsia / Pregnancy-induced hypertension / Cesarean section / Maternal inpatient admission during pregnancy / Preterm delivery (<37 gestation weeks) / Extreme prematurity (<32 gestation weeks) / 5-min Apgar score / Phototherapy / Neonatal respiratory distress syndrome / Intrauterine fetal or neonatal death / Admission to neonatal intensive care unit / Malformations
C. Quality of life / satisfaction questionnaires
D. Gestational weight gain / Hypoglycemia / Gastro-intestinal side effects
E. Results of oral glucose tolerance test / Weight changes 3 months after delivery
F. Future biochemical measurements |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Birth and 12 to 16 weeks after delivery |
Naissance et 12 à 16 semaines après l'accouchement |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | No |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 29 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 3 |
E.8.9.1 | In the Member State concerned months | 8 |
E.8.9.1 | In the Member State concerned days | 0 |